JNK3 Is Required for the Cytoprotective Effect of Exendin 4

• Hélène Ezanno,
• Valérie Pawlowski,
• Saida Abdelli,
• Raphael Boutry,
• Valery Gmyr,
• Julie Kerr-Conte,
• Christophe Bonny,
• François Pattou,
• Amar Abderrahmani

Affiliations

Hélène Ezanno

Lille 2 University, University of Lille Nord de France, European Genomic Institute for Diabetes, EGID FR 3508, UMR 8199, Lille, France

Valérie Pawlowski

Lille 2 University, University of Lille Nord de France, European Genomic Institute for Diabetes, EGID FR 3508, UMR 8199, Lille, France

Saida Abdelli

Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, 1011 Lausanne, Switzerland

Raphael Boutry

Lille 2 University, University of Lille Nord de France, European Genomic Institute for Diabetes, EGID FR 3508, UMR 8199, Lille, France

Valery Gmyr

Department of Endocrine Surgery, Lille 2 University, University of Lille Nord de France, Lille University Hospital, INSERM UMR 859, Biotherapies for Diabetes, European Genomic Institute for Diabetes, Lille, France

Julie Kerr-Conte

Department of Endocrine Surgery, Lille 2 University, University of Lille Nord de France, Lille University Hospital, INSERM UMR 859, Biotherapies for Diabetes, European Genomic Institute for Diabetes, Lille, France

Christophe Bonny

Service of Medical Genetics, Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, 1011 Lausanne, Switzerland

François Pattou

Department of Endocrine Surgery, Lille 2 University, University of Lille Nord de France, Lille University Hospital, INSERM UMR 859, Biotherapies for Diabetes, European Genomic Institute for Diabetes, Lille, France

Amar Abderrahmani

Lille 2 University, University of Lille Nord de France, European Genomic Institute for Diabetes, EGID FR 3508, UMR 8199, Lille, France